{"id":17428,"date":"2023-02-11T17:19:56","date_gmt":"2023-02-11T16:19:56","guid":{"rendered":"http:\/\/mabdesign.fr\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/"},"modified":"2023-02-11T17:19:56","modified_gmt":"2023-02-11T16:19:56","slug":"pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/","title":{"rendered":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)"},"content":{"rendered":"

Pierre Fabre to commercialize and distribute the first approved allogeneic T-cell immunotherapy in Europe following transfer of the European Commission Marketing Authorization of EBVALLO\u00ae (tabelecleucel)<\/strong><\/p>\n

CASTRES, France & THOUSAND OAKS, Calif. USA – February 8, 2023 – Pierre Fabre<\/strong> and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO\u00ae (tabelecleucel) for patients with relapsed or refractory Epstein\u2011Barr virus positive post\u2011transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre. From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets. Pierre Fabre is planning to launch EBVALLO\u00ae in the first European countries during quarter one of 2023.
\n\u201cWe are delighted that, at Pierre Fabre, we will now be able to make EBVALLO\u00ae available to patients with Epstein\u2011Barr virus positive post\u2011transplant lymphoproliferative disease (EBV+ PTLD) as quickly as possible,\u201d said Eric Ducournau, CEO of Pierre Fabre. \u201cAs a Company, we are passionate in accelerating the development and delivery of ground-breaking treatments for solid tumors, hematologic malignancies and rare diseases. With EBVALLO\u00ae being the only approved therapy for EU patients affected by EBV+ PTLD, this is a significant milestone for people diagnosed with this rare and potentially deadly cancer and an important step forward in our commitment to addressing clinical challenges with solutions once considered unimaginable.\u201d To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-17428","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"\nPierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel) - MabDesign<\/title>\n<meta name=\"description\" content=\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel) - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-11T16:19:56+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)\",\"datePublished\":\"2023-02-11T16:19:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\"},\"wordCount\":238,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\",\"name\":\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel) - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2023-02-11T16:19:56+00:00\",\"description\":\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel) - MabDesign","description":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/","og_locale":"en_US","og_type":"article","og_title":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel) - MabDesign","og_description":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)","og_url":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/","og_site_name":"MabDesign","article_published_time":"2023-02-11T16:19:56+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)","datePublished":"2023-02-11T16:19:56+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/"},"wordCount":238,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/","url":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/","name":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel) - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2023-02-11T16:19:56+00:00","description":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/pierre-fabre-to-commercialize-and-distribute-atara-ebvallo-tabelecleucel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Pierre Fabre to commercialize and distribute ATARA EBVALLO\u00ae (tabelecleucel)"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17428"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17428\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}